Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus

Chinese Medical Journal

Volumn 122, Issue 21, 2009, Pages 2560-2566

  Du, Jian Ling ^a   Liu, Jian Feng ^b   Men, Li Li ^a   Yao, Jun Jie ^a   Sun, Li Peng ^a   Sun, Guo Hua ^a   Song, Gui Rong ^a   Yang, Yu ^a   Bai, Ran ^a   Xing, Qian ^a   Li, Chang Chen ^a   Sun, Chang Kai ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Cangzhou People's Hospital   (China)

Author keywords

Intensive multifactorial intervention; Macroangiopathy; Serum amyloid A; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHINESE DRUG; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SERUM AMYLOID A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XUE ZHI KANG;

ADULT; AGED; ANGINA PECTORIS; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC PATIENT; DIET; DISEASE DURATION; DYSLIPIDEMIA; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN TREATMENT; INTERVENTION STUDY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PROPHYLAXIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SERUM AMYLOID A PROTEIN; TRIGLYCERIDES; TUNICA MEDIA;

EID: 73449108083     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.21.007     Document Type: Article

References (24)

1. Ross R. AS: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Libby P, Ridker PM, Maseri A. Inflammation and AS. Circulation 2002; 105: 1135-1143.
3. Gruys E. Protein folding pathology in domestic animals. J Zhejiang Univ Sci 2004; 5: 1226-1238.
4. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-523.
5. Chait A, Han CY, Oram JF, Heinecke JW. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005; 46: 389-403.
6. Sjoholm K, Palming J, Olofsson LE, Gummesson A, Svensson PA, Lystig TC, et al. A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 2005; 90: 2233-2239.
7. Poitou C, Vigucric N, Cancello R, De Matteis R, Cinti S, stich V, et al. Serum amyloid A: Production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005; 48: 519-528.
8. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006; 3: e287.
9. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
10. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
11. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006; 29: 329-333.
12. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-732.
13. Leinonen ES, Hiukka A, Hurt-Camejo E, Wiklund O, Sarna SS, Mattson HL, et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J Intern Med 2004; 256: 119-127.
14. Yang Y, Du JL, Zhang XJ, Bai R, Ba Y, Xing Q, et al. Association between serum amyloid A and intima-media thickness (IMT) of common carotid artery in patients with type 2 diabetes. Chin J Endocrinol Metab (Chin) 2008; 24: 188-189.
15. Zhang T, Bai R, Zhang H, Liu JH, Yang Y, Ba Y, et al. The relationship between C-reactive protein and glycemic control in short duration diabetic patients. Chin J Diabetes (Chin) 2006; 14: 372-373.
16. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 1971-1977.
17. Hamano M, Saito M, Eto M, Nishimatsu S, Suda H, Matsuda M, et al. Serum amyloid A, C-reactive protein and remnant-like lipoprotein particle cholesterol in type 2 diabetic patients with coronary heart disease. Ann Clin Biochem 2004; 41: 125-129.
18. Hartqe MM, Unqer T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 2007; 4: 84-88.
19. Sanchez PL, Morinigo JL, Pabon P, Martin F, Piedra I. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart 2004; 90: 264-269.
20. Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 2006; 186: 396-401.
21. Blake GJ, Ridker PM. C-reactive protein, subclinical AS, and risk of cardiovascular events. Arterioscler Thromb Vasc Biol 2002; 22: 1512-1513.
22. Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004; 27: 2918-2924.
23. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pederson O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
24. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.